《新股消息》和黃醫藥(00013.HK)公開超購4.2倍 一手中籤率60%
長和(00001.HK)旗下生物醫藥公司和黃醫藥(00013.HK)(HCM.US)公佈招股結果,計劃發售1.04億股股份,當中12.5%在港公開發售,本港公開發售錄超購4.23倍,國際配售超購4倍。發售價已釐定爲每股發售股份40.1元,一手500股中籤率爲60%。該股明日(30日)掛牌上市,摩根士丹利、Jefferies及中金爲聯席保薦人。
公司是次招股引入5名基石投資者,包括CA Fern Parent、CPP Investments、泛大西洋投資集團、HBM Healthcare Investments及中金啓融基金等,合共認購6,321.55萬股股份,佔緊隨全球發售完成後公司已發行股本約7.5%。
和黃醫藥指其美國預託證券(每份代表五股股份)於納斯達克上市買賣,其美國預託證券於納斯達克的最新報價爲每份美國預託證券33.5美元。
公司預計,全球發售所得款項淨額將約爲39.5億元,當中50%用於推進賽沃替尼、索凡替尼、(口夫)(口奎)替尼、HMPL-689及HMPL-523的後期臨牀計劃以進行註冊試驗及潛在提交NDA申請;10%將用於支持進一步的概念驗證研究,並資助內部研究以持續擴大的癌症及免疫疾病產品組合;20%將用於進一步增強集團在商業化、臨牀、監管及生產方面的綜合實力;15%將爲潛在的全球業務發展及策略收購機會提供資金;餘下5%將用作營運資金、在全球及中國擴大內部能力以及一般企業用途的資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.